3 Stocks Pushing The Health Care Sector Lower

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

Two out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading up 15 points (0.1%) at 12,980 as of Tuesday, Dec. 4, 2012, 11:49 AM ET. The NYSE advances/declines ratio sits at 1,319 issues advancing vs. 1,553 declining with 162 unchanged.

The Health Care sector currently sits down 0.3% versus the S&P 500, which is down 0.1%. Top gainers within the sector include Edwards Life ( EW), up 4.5%, Shire ( SHPG), up 2.7%, Valeant Pharmaceuticals International ( VRX), up 1.1%, Abbott Laboratories ( ABT), up 0.8% and GlaxoSmithKline ( GSK), up 0.8%.

TheStreet Ratings group would like to highlight 3 stocks pushing the sector lower today:

3. BioMarin Pharmaceuticals ( BMRN) is one of the companies pushing the Health Care sector lower today. As of noon trading, BioMarin Pharmaceuticals is down $0.88 (-1.8%) to $47.81 on light volume Thus far, 155,248 shares of BioMarin Pharmaceuticals exchanged hands as compared to its average daily volume of 1.7 million shares. The stock has ranged in price between $47.72-$48.66 after having opened the day at $48.58 as compared to the previous trading day's close of $48.69.

BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and rest of the world. BioMarin Pharmaceuticals has a market cap of $6.0 billion and is part of the drugs industry. Shares are up 41.6% year to date as of the close of trading on Monday. Currently there are 11 analysts that rate BioMarin Pharmaceuticals a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates BioMarin Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity and feeble growth in the company's earnings per share. Get the full BioMarin Pharmaceuticals Ratings Report now.

EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass

2. As of noon trading, Regeneron Pharmaceuticals ( REGN) is down $1.32 (-0.7%) to $179.38 on light volume Thus far, 174,904 shares of Regeneron Pharmaceuticals exchanged hands as compared to its average daily volume of 805,100 shares. The stock has ranged in price between $177.71-$180.77 after having opened the day at $180.30 as compared to the previous trading day's close of $180.70.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines for the treatment of serious medical conditions in the United States. Regeneron Pharmaceuticals has a market cap of $16.7 billion and is part of the drugs industry. The company has a P/E ratio of 89.6, above the S&P 500 P/E ratio of 17.7. Shares are up 218.5% year to date as of the close of trading on Monday. Currently there are 9 analysts that rate Regeneron Pharmaceuticals a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Regeneron Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and good cash flow from operations. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Regeneron Pharmaceuticals Ratings Report now.

EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass

1. As of noon trading, Baxter International ( BAX) is down $0.75 (-1.1%) to $65.05 on average volume Thus far, 1.6 million shares of Baxter International exchanged hands as compared to its average daily volume of 3.1 million shares. The stock has ranged in price between $64.92-$65.89 after having opened the day at $65.60 as compared to the previous trading day's close of $65.80.

Baxter International Inc., through its subsidiaries, develops, manufactures, and markets products for people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. Baxter International has a market cap of $36.4 billion and is part of the health services industry. The company has a P/E ratio of 16.1, below the S&P 500 P/E ratio of 17.7. Shares are up 33.9% year to date as of the close of trading on Monday. Currently there are 12 analysts that rate Baxter International a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates Baxter International as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, increase in net income, notable return on equity, growth in earnings per share and expanding profit margins. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Baxter International Ratings Report now.

EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass

If you are interested in one of these 5 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

A reminder about TheStreet Ratings group: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

null

More from Markets

Data Regulation on FAANG's Could Just Be Underway: Cramer's Investing Teach-in

Data Regulation on FAANG's Could Just Be Underway: Cramer's Investing Teach-in

Your Need to Know - Forward Look

Your Need to Know - Forward Look

3 Things Investors Can Do to Stay Strategic When the Market's Volatile

3 Things Investors Can Do to Stay Strategic When the Market's Volatile

How to Be a Tactical Investor in the Current Market

How to Be a Tactical Investor in the Current Market

How E-Mini S&P 500 Revolutionized Equity, Electronic Trading

How E-Mini S&P 500 Revolutionized Equity, Electronic Trading